SCHEMBL13855946

SCHEMBL13855946

CC(=O)NC1C(OCC2OC(O)C(NC(C)=O)C(OC3OC(CO)C(O)C(O)[C@@H]3O)C2O)OC(CO)C(OC2OC(CO)C(O)C(O)[C@@H]2O)C1O

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.66
▸ LGALS8 O00214 1/20 0.66
▸ LGALS4 P56470 1/20 0.66
▸ MAPK1 P28482 2/20 0.54
▸ LGALS1 P09382 1/20 0.49
▸ LGALS7; LGALS7B P47929 1/20 0.49
▸ CD69 Q07108 1/20 0.48
▸ CHIA Q9BZP6 1/20 0.47
▸ AMY2A P04746 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ CD209 Q9NNX6 2/20 0.46
▸ LGALS9 O00182 1/20 0.45
▸ ENGASE Q8NFI3 1/20 0.45
▸ HPSE Q9Y251 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577686 1.00 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL30185411 1.00 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL26491880 1.00 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL29407986 0.99 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL30185426 0.98 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL30267118 0.98 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL30185407 0.96 LGALS3 (0.61) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL31139964 0.96 LGALS3 (0.61) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL30527825 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1LGALS1
SCHEMBL29511801 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1LGALS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090117106-A1 Cancer Specific Glycans and Use Thereof GLYKOS FINLAND OY (FI) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117106-A1 Cancer Specific Glycans and Use Thereof SIGLEC7, FUT5, SIGLEC9 LGALS3 9/4885LGALS8 53/4885LGALS4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback